A Randomized, Double-Blind, Placebo-Controlled, Five Parallel Groups Efficacy and Safety Study of NS 2330 (Tesofensine) (0.125 mg, 0.25 mg, 0.5 mg and 1.0 mg) Administered Orally Once Daily Over 14 Weeks in Levodopa Treated Parkinson Patients With Motor Fluctuations

This study has been completed.

Study NCT00148512 Information provided by Boehringer Ingelheim Pharmaceuticals

First Received: September 7, 2005 Last Updated: January 12, 2007 History of Changes

No Study Results Posted for this Study

Study Status:	This study has been completed.
Estimated Study Completion Date:	February 2005
Estimated Primary Completion Date:	No date given